Gymiso

Gymiso is an oral medication that contains the active ingredient misoprostol, a prostaglandin E1 analog. It is marketed in the European Union as a prescription product. Misoprostol works by stimulating prostaglandin receptors, which increases gastric mucus and bicarbonate secretion and promotes uterine smooth‑muscle contraction. It is intended for use and is listed under ATC code A02BX02.

Gymiso is prescribed for several clinical situations where prostaglandin activity is beneficial.

- Prevention of gastric ulcers associated with non‑steroidal anti‑inflammatory drugs (NSAIDs). - Induction of labor in term pregnancies when cervical readiness is required. - Medical termination of early pregnancy as part of a regimen with mifepristone. - Cervical ripening prior to surgical or obstetric procedures.

Misoprostol may cause a range of effects, most of which are related to its action on the gastrointestinal tract and uterus.

Common: - Abdominal cramping or pain. - Diarrhea or loose stools. - Nausea or vomiting. - Fever or chills. - Headache.

Serious: - Severe uterine bleeding. - Persistent vomiting leading to dehydration. - Signs of infection such as fever with abdominal pain. - Allergic reactions including rash, swelling, or difficulty breathing.

When prescribing Gymiso, clinicians should evaluate patient history and monitor for conditions that could be worsened by prostaglandin effects.

- Avoid use in patients with known hypersensitivity to misoprostol or other prostaglandin analogues. - Use caution in individuals with cardiovascular disease, hypertension, or asthma. - Do not administer to women with a viable intrauterine pregnancy unless termination is intended. - Assess renal or hepatic impairment before initiating therapy. - Consider the risk of uterine hyperstimulation when used for labor induction. - Pregnancy category is not established; discuss potential fetal risks with pregnant patients.

Gymiso can interact with other medicines, altering its efficacy or increasing the likelihood of adverse events.

Avoid: - Concurrent use with potent uterotonics (e.g., oxytocin) that may cause excessive uterine contractions. - Co‑administration with NSAIDs that require gastric protection, as misoprostol may be insufficient alone. - Combination with drugs that significantly lower blood pressure, such as antihypertensives, may exacerbate hypotension.

Use with caution: - Antacids or proton‑pump inhibitors may reduce the gastric protective effect of misoprostol. - CYP450‑inducing agents (e.g., rifampin, carbamazepine) could decrease misoprostol plasma levels. - Drugs that prolong the QT interval should be monitored when used together.